This stock, like many other chinese small caps, needs to do two things -- make their numbers, and stay out of the news.
To my knowledge there is no 2011 guidance for CNAM. Obviously there wont be much confidence in guidance that is provided, should they give some, given last year.
If they make their numbers, though, I don't see why CNAM can't trade at 6x trailing EPS, which could easily put this thing at $8.
They are going to need a new auditor. CNAM is too small and cheap to attract short attention but a run from 2 to 8 coupled with a no name auditor with a troubled past is just asking for it in today's environment.
2-4 years out, if / when china has cleaned up its act on corporate governence, multiple expansion + good growth could give this thing biotech like returns.
News 
Market Data 
Discover 
